智通财经APP获悉，太平洋证券发布研报称，维持环球医疗(02666)"买入"评级，预计2025-2027年公司 营业收入为147.23、153.43、162.54亿元，归母净利润为21.18、22.28、23.66亿元，EPS为1.12、1.18、 1.25元，对应10月29日收盘价的PE估值为4.99、4.75、4.47倍。看好公司医疗健康业务高速增长带来的 估值提升，给予2025年6.5倍PE估值，对应目标价7.97港元。公司医疗健康业务成为核心增长引擎，金 融业务保持稳健且风控成效显著，两大业务板块协同效应持续夯实公司价值。 事件：环球医疗发布2025年半年度报告。报告期内，公司实现收入75.81亿元，同比+15.9%;实现期内溢 利13.35亿元，同比+6.6%;实现普通股权益持有人应占期内溢利12.28亿元，同比+8.0%。 太平洋证券主要观点如下： 公司经营业绩延续稳健增长态势 截至2025H1，公司基本每股收益0.65元，同比+8.0%;股本回报率为14.08%，总资产回报率为3.11%。从 收入结构看，医疗健康业务2025H1实现收入49.64亿元，占总营收比重提升至65.5%，同比+27.7 ...

Core Viewpoint - Pacific Securities maintains a "Buy" rating for Universal Medical (02666), projecting revenue growth from 147.23 billion to 162.54 billion CNY and net profit growth from 21.18 billion to 23.66 billion CNY from 2025 to 2027, with an estimated PE ratio decreasing from 4.99 to 4.47 times [1] Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 75.81 billion CNY, a year-on-year increase of 15.9%, and a profit of 13.35 billion CNY, up 6.6% [1] - Basic earnings per share for 2025H1 were 0.65 CNY, reflecting an 8.0% increase year-on-year, with a return on equity of 14.08% and a return on total assets of 3.11% [1] - The medical health segment generated 49.64 billion CNY in revenue, accounting for 65.5% of total revenue, with a year-on-year growth of 27.7% [2] Group 2: Medical Health Business - The medical health segment is the core growth driver, with significant contributions from three areas: 1. Comprehensive medical services with 65 hospitals and over 16,000 beds, despite a 14.6% decline in profit to 2.31 billion CNY due to external pressures [2] 2. Specialized medical services, including the acquisition of Shandong University of Traditional Chinese Medicine Affiliated Eye Hospital [2] 3. Health technology revenue reached 6.46 billion CNY, a remarkable 142.1% increase, managing assets worth 370 billion CNY across over 1,600 institutions [2] Group 3: Financial Business - The financial business, focusing on medical financing leasing, generated 28.51 billion CNY in revenue, a 6.9% increase year-on-year [3] - The financial segment's non-performing asset ratio was 0.97%, with a provision coverage ratio of 313.87%, indicating strong risk management capabilities [3] - The average cost of interest-bearing liabilities decreased by 44 basis points to 3.40%, enhancing both risk resistance and cost control [3]

来源：金融界 专利摘要显示，本文涉及金融业务风控领域，尤其涉及一种非法资金合法化风险团队、用户的检测方 法、装置，其中，非法资金合法化风险团队检测方法包括：获取基于知识图谱划分的团队；分别判断所 述团队中每个成员是否命中预警规则，根据是否命中预警规则匹配不同机器学习模型，得到所述团队中 每个成员的非法资金合法化风险概率，从而确定所述团队的非法资金合法化风险检测结果。本文解决了 团队非法资金合法化风险定量化分析困难，以及个人非法资金合法化风险检测效果差、成本高的问题。 天眼查资料显示，中信银行股份有限公司，成立于1987年，位于北京市，是一家以从事货币金融服务为 主的企业。企业注册资本4893479.6573万人民币，实缴资本3140699.2773万人民币。通过天眼查大数据 分析，中信银行股份有限公司共对外投资了11家企业，参与招投标项目5000次，财产线索方面有商标信 息187条，专利信息1430条，此外企业还拥有行政许可154个。 中信银行申请一种非法资金合法化风险团队、用户 检测方法专利，解决定量化分析困难等问题 金融界2025年3月26日消息，国家知识产权局信息显示，中信银行股份有限公司申请一项名为" ...